Inducible nitric oxide synthase as a potential blood-based biomarker in inflammatory bowel diseases
Gastroenterology and Hepatology from Bed to Bench,
Vol. 11 No. Supplement 1 (2018),
11 December 2018
,
Page s124-s128
https://doi.org/10.22037/ghfbb.v0i0.1527
Abstract
Aim: Here, we evaluated the role of (iNOS) as a blood-based biomarker of inflammatory bowel diseases (IBD).
Background: Up-regulation of inducible nitric oxide synthase (iNOS) in the intestinal epithelial cells has been closely associated with the initiation and maintenance of intestinal inflammation in IBD.
Methods: In a case-control design, 59 IBD patients and 30 healthy control subjects were participated in this study. A total of 10 ml blood sample was taken from each participant. Blood leukocytes were isolated and iNOS mRNA expression level was evaluated in the isolated leukocytes using relative quantitative Real-time PCR.
Results: The patients’ population included 40 ulcerative colitis (UC) and 19 Crohn's disease (CD) patients. The flare and remission phase of disease were seen in 43 and 16 patients, respectively. The mean iNOS mRNA expression was not significantly different between the IBD patients and healthy controls (p=0.056). The mean iNOS mRNA expression was significantly higher in the flare phase of the disease compared to the remission phase (p=0.039). No significant difference was observed between the mean iNOS mRNA expression in the blood leukocytes of UC and CD patients (p=0.82).
Conclusion: iNOS is differently expressed in the blood leukocytes of active vs. inactive IBD disease. Thus, it could be potentially used as a non-invasive blood-based biomarker of IBD.
Keywords: Inflammatory bowel diseases, Inducible nitric oxide synthase, Biomarker.
(Please cite as: Baranipour S, Amini Kadijani A, Qujeq D, Shahrokh SH, Haghazali M, MirzaeiA, et al. Inducible nitric oxide synthase as a potential blood-based biomarker in inflammatory bowel diseases. Gastroenterol Hepatol Bed Bench 2018;11(Suppl. 1):S124-S128).
- Inflammatory bowel diseases
- Inducible nitric oxide synthase
- Biomarker.
How to Cite
References
Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflam Res 2014;7:113.
Ng SC. Emerging trends of inflammatory bowel disease in Asia. Gastroenterol Hepatolo 2016;12:193.
Viennois E, Zhao Y, Merlin D. Biomarkers of inflammatory bowel disease: from classical laboratory tools to personalized medicine. Inflamm Bowel Dis 2015;21:2467-74.
Karbalaei R, Piran M, Rezaei-Tavirani M, Asadzadeh-Aghdaei H, Heidari MH. A systems biology analysis protein-protein interaction of NASH and IBD based on comprehensive gene information. Gastroenterol Hepatol Bed Bench. 2017;10:194-201.
Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunol 2004;113:427-37.
Dijkstra G, Zandvoort AJ, Kobold AM, Jager-Krikken AD, Heeringa P, Goor Hv, et al. Increased expression of inducible nitric oxide synthase in circulating monocytes from patients with active inflammatory bowel disease. Scan J Gastroenterol 2002;37:546-54.
Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983-9.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med 1987;317:1625-9.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008;3:1101.
Benaitreau D, Dieudonné MN, Dos Santos E, Leneveu MC, Mazancourt Pd, Pecquery R. Antiproliferative effects of adiponectin on human trophoblastic cell lines JEG-3 and BeWo. Biol Reprod 2009;80:1107-14.
Kim YG, Jang BI. The role of colonoscopy in inflammatory bowel disease. Clin Endosc 2013;46:317.
Asadzadeh-Aghdaee H, Shahrokh S, Norouzinia M, Hosseini M, Keramatinia A, Jamalan M, et al. Introduction of inflammatory bowel disease biomarkers panel using protein-protein interaction (PPI) network analysis. Gastroenterol Hepatol Bed Bench 2016;9 Suppl 1:8.
Burakoff R, Pabby V, Onyewadume L, Odze R, Adackapara C, Wang W, et al. Blood-based biomarkers used to predict disease activity in Crohn's disease and ulcerative colitis. Inflam Bowel Dis 2015;21:1132-40.
Amini AK, Asadzadeh HA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, et al. Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease. Clin Translat Gastroenterol 2017;8:e117.
Aghdaei HA, Kadijani AA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, et al. An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United European Gastroenterol J 2018;6: 1074-1081.
Taghipour N, Aghdaei HA, Haghighi A, Mossafa N, Tabaei SJ, Rostami-Nejad M. Potential treatment of inflammatory bowel disease: a review of helminths therapy. Gastroenterol Hepatol Bed Bench. 2014;7:9-16.
Boughton-Smith N, Evans S, Whittle B, Moncada S, Hawkey C, Cole A, et al. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993;342:338- 40.
Lundberg J, Hellström P, Lundberg J, Alving K. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet 1994;344:1673-4.
Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterol 1996;111:871-85.
Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005;11:7227.
Baillie J, Soltis R. Systemic complications of inflammatory bowel disease. Geriatrics 1985;40:53-6.
- Abstract Viewed: 122 times
- PDF Downloaded: 120 times